Podcasts about Gastroenterology

Send a textWhen your scope looks great but your day still falls apart, something's missing. We sit down with Dr. Dawn Beaulieu, a Vanderbilt IBD specialist certified in functional medicine, to unpack a root-cause approach that complements biologics and brings relief where patients feel it most: sleep, fatigue, bowel consistency, and energy.We get specific about what functional medicine actually is—science-based, holistic, and individualized—then trace how Dr. Beaulieu integrates it into a busy academic IBD center. From the “functional medicine tree” and Five Rs to team-based care with dietitians and social workers, she shows how nutrition, hydration, and nervous system training shift the gut-brain axis. We talk real-world food strategies that work for sensitive guts, why ultra-processed ingredients and dyes upset the microbiome, and how to ramp fiber without misery. She shares outcomes from Vanderbilt's group programs, where patients improved quality-of-life, sleep, and fatigue in about twelve weeks, with some showing lower fecal calprotectin.We also tackle supplements with nuance: which nutrients many IBD patients actually need, how to choose third‑party tested brands, and why you can't out-supplement a bad diet. Dr. Beaulieu sets clear lines on when medication is essential for moderate to severe disease, then explores where GLP‑1 drugs may help overweight patients alongside standard care. Access matters too, so we highlight ways to find certified functional medicine providers, piece together a local team, and use tools like HRV training and Nerva to build daily resilience.This is a grounded, empowering roadmap for anyone stuck between “remission” and “feeling well.” If the goal is fewer flares and more life, these are the levers you can pull today—without abandoning the therapies that work. Follow the show, share this episode with someone who needs a nudge toward better routines, and leave a review to help more people find the conversation.Links: Find a practitioner- Institute for Functional MedicineIBD Learning slides "Functional Medicine and Inflammatory Bowel Disease" with Dr. Beaulieu- Crohn's & Colitis Foundation USAPodcast with Dr. Beaulieu on FMP EssentialsPodcast episode with Dr. Beaulieu on The Dr. Mark Hyman ShowLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Have you longed to integrate your Christian faith into your patient care—on the mission field abroad, in your work in the US, and during your training? Are you not sure how to do this in a caring, ethical, sensitive, and relevant manner? This “working” session will explore the ethical basis for spiritual care and provide you with professional, timely, and proven practical methods to care for the whole person in the clinical setting. https://www.dropbox.com/scl/fi/qpah9kh1lttg6cm1jjop9/Bob-Mason-Ethics-of-Spiritual-Care-revised.pptx?rlkey=0emve2ja8282nv8xc4uinq1hg&st=9033htwx&dl=0

In this episode of the Gut Doctor podcast, Dr. Parikh discusses the current treatment landscape of constipation with Dr. Satish Rao. Dr. Rao is Chair of Gastroenterology, Professor of Medicine, and Director of Neurogastroenterology and Motility at August University. This episode was sponsored by Vibrant Gastro, makers of the drug-free Vibrant System.

February 16, 2026 ~ Dr. Sumit Singla, MD, Senior Staff, Advanced Therapeutic Endoscopy. Chief of Gastroenterology and Hepatology, Henry Ford Health discusses the spike in colorectal cancer deaths in people under 50 after James Van Der Beek dies at 48. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Eric k. Mangiardi, Biotech CEO of Q3 Medical Device Limited, located in Dublin Ireland, shares his unique perspective on health care delivery with innovative biodegradable stents useful in Gastroenterology, Urology and beyond.

Those who hope to honor God and advance Jesus' Kingdom face powerful opposition from spiritual, physical, and psychological enemies. Successful launching and long term fruitfulness depends on recognizing and, in dependence on the Holy Spirit, waging war against those enemies.

Gluten-free diets were initially intended for children with medical conditions such as celiac disease, wheat allergy, and non-celiac gluten sensitivity A review published in Frontiers in Nutrition found that gluten-free diets, when not medically required, can cause nutrient gaps and raise health risks for children A recent study in The American Journal of Gastroenterology found that young patients exhibited a significant increase in urinary arsenic and other metal levels after only six months on a gluten-free diet When cooked properly, white rice can be a smarter choice than brown rice because it's easier to digest, contains less arsenic and heavy metals Instead of cutting out foods that are good for your gut, include healthy carbs, choose stable fats over seed oils, and learn to calm your food fears

Send us a textRemission rates don't rise by accident—they rise when people, data, and purpose align. This week we were joined by our friend Becky Johnson Rescola, Executive Director and President of Improve Care Now (ICN), to unpack how a learning health network is transforming pediatric IBD care through shared data, quality improvement, and genuine partnership with families.We trace ICN's journey from ten centers in 2007 to a 100+ site network with a registry tracking over 33,000 active kids and young adults. Becky explains how consistent measurement and coaching improved remission rates, with growing emphasis on sustained and steroid‑free remission. You'll hear a real-time example of change in motion: a shared decision-making tool piloted at eight centers to help families weigh adalimumab plus methotrexate, reflecting registry findings that combo therapy speeds remission with adalimumab but not infliximab. We also dig into how registry data supports off‑label insights, helps sponsors understand pediatric outcomes, and even flags potential trial participants through privacy‑preserving queries.Beyond medications, we explore EMR integration with Epic to reduce data burden, targeted efforts to close gaps in race and ethnicity fields to spot disparities, and the network's commitment to co‑producing resources with patients and parents. Becky brings the community to life through ICN's conferences—scholarships, learning labs, and a welcoming vibe that empowers quieter voices to speak up and help set the agenda. From very early onset IBD and tailored transition to adult care, to smarter partnerships across GI and related conditions, the path forward is both practical and ambitious: make evidence usable, make participation easy, and make sure every child benefits whether or not they're seen at an ICN center.If this conversation sparks ideas or gives you hope, help us spread the word—follow the show, share it with someone who needs it, and leave a review with the question you want us to tackle next.LinksImprove Care Now's websiteICN- Tools and resources for patients and parentsLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Medical missionaries often feel powerful emotional burden from moral injury, and it is a leading cause of departure from the mission field. But we have learned proven methods of preventing and dealing with moral injury. Use God’s powerful methods to protect yourself and your team, and to grow in wisdom and spirit!

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.Topics covered include:Mechanisms of pruritus and fatigue in PBCNonpharmacologic treatment optionsAn overview of clinical trial data supporting second-line agents for symptom management:BezafibrateElafibranorSeladelparInvestigational agents:VolixibatLinerixibatSetanaxibThis episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.Topics covered include:Available agents for second-line treatment of PBCAn overview of clinical trial data supporting second-line agents:Obeticholic acid (OCA)BezafibrateElafibranorSeladelparThis episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3rPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:How and when to assess treatment responseRisk factors in PBCBiochemical treatment response and fibrosis stage as predictors of transplant-free survivalDynamics of liver stiffness measurements and clinical outcomes in PBCThe importance of bilirubin and alkaline phosphatase normalizationThis episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: Methods of Assessing PBC Disease ProgressionNewer Agents for Second-line Treatment of PBCPrioritizing Symptom Management and Quality of Life With PBC TreatmentPresenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fiber isn't one-size-fits-all and for some people, more isn't better. In this episode, we explore why most people under-eat fiber, why certain fibers can worsen symptoms, and how to personalize intake in a way your body can actually tolerate. Dr. Heather Armstrong shares emerging insights on fiber function, microbiome capacity, and practical strategies for going low and slow. We also unpack new science explaining why fiber supports gut health in some individuals, while triggering issues in others with reduced fermentative activity. In this episode, we discuss: • The fiber gap, health risks, and minimum intake targets • How solubility, viscosity, and fermentability guide fiber choice • Matching fiber types to IBS, diarrhea, and constipation • Why whole foods matter more than isolates • Citrus peel pectin and simple kitchen hacks • Why “low and slow” dosing reduces gas and pain • How long microbiome changes and symptom relief actually take • When fiber supplements help (and when they don't) • Individualized fiber needs in IBD (and implications for IBS, MS, and liver disease) • Why dietitians are essential for precision nutritionThis episode is especially relevant if you've been told to “just eat more fiber”—and it didn't go well.Learn more about Dr. Heather Armstrong's novel research:Gut feeling: new test and precision diet could boost health for people with IBD. U of A research team in clinical trials for their innovative AI-powered tool that could reduce inflammation by “rewiring” the gut microbiome.References:Ramezani F, Pourghazi F, Eslami M, et al. Dietary fiber intake and all-cause and cause-specific mortality: An updated systematic review and meta-analysis of prospective cohort studies. Clin Nutr. 2024Chang SC, Cassidy A, Willett WC, Rimm EB, O'Reilly EJ, Okereke OI. Dietary flavonoid intake and risk of incident depression in midlife and older women. Am J Clin Nutr. 2016 Armstrong HK, Bording-Jorgensen M, Santer DM, et al. Unfermented β-fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients. Gastroenterology. 2023Armstrong H, Mander I, Zhang Z, Armstrong D, Wine E. Not All Fibers Are Born Equal; Variable Response to Dietary Fiber Subtypes in IBD. Front Pediatr. 2021Gao J, Lee AA, Abtahi S, et al. Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial. Gastroenterology. This episode is sponsored by Activia.Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

Liver disease isn't just about alcohol, and it's way more common than most people realize.   In this episode of The Gut Show, @socalgastrodoc helps break down what your liver actually does, why cases are rising, how it's diagnosed, what's reversible, and where things like GLP-1s, supplements, and even coffee fit in.   If you've ever been told to "just drink less" or felt overwhelmed by perfection, this one's for you!   About our guest:  Dr. Wendi LeBrett is a double board-certified gastroenterologist and internal medicine physician. She holds a Bachelor of Arts in Economics from Stanford University and graduated from the University of California San Diego School of Medicine. She completed her internal medicine residency and gastroenterology subspecialty fellowship at UCLA. Her research has been published in several leading gastroenterology journals including Gastroenterology, The American Journal of Gastroenterology, Clinical Gastroenterology & Hepatology, and The Lancet Gastroenterology. Dr. LeBrett is a leading voice in gastroenterology on social media. She presented the presidential plenary at United European Gastroenterology Week 2025 on medical misinformation on social media and was awarded a Healio Gastroenterology Disruptor award as Social Media Influencer of the Year 2023. She has over 300K followers on social media and creates educational content as @socalgastrodoc. She is a trusted voice on gastrointestinal health and has been featured in the Wall Street Journal, TIME, SELF, the Huffington Post, Business Insider and Well+Good. She is the founder of ModernGut, a gastroenterology education platform. TikTok Instagram   Thank you to our partners:   @imodifyhealth is the leader in evidence-based, medically-tailored meal delivery offering Monash Certified low FODMAP, Gluten free, and Mediterranean meals - expertly crafted to help you achieve better symptom control AND improve overall health.    The best part? They make it easy by doing all prep work for you. Simply choose the meals you want, stock your fridge or freezer when meals arrive at your door, then heat and enjoy when you're ready. Delicious meals. Less stress. Complete peace of mind.   Check out modifyhealth.com and save 35% off your first order plus free shipping across the US with code: THEGUTSHOW.   @fodzyme is the world's first enzyme supplement specialized to target FODMAPs.   When sprinkled on or mixed with high-FODMAP meals, FODZYME's novel patent-pending enzyme blend breaks down fructan, GOS and lactose before they can trigger bloating, gas and other digestive issues.    With FODZYME, enjoy garlic, onion, wheat, brussels sprouts, beans, dairy and more — worry free! Discover the power of FODZYME's digestive enzyme blend and eat the foods you love and miss.   Visit fodzyme.com and save 20% off your first order with code THEGUTSHOW. One use per customer.   @mbiotaelemental is the next generation of the elemental diet. Developed with leading gastroenterologists and food scientists, it's the first formula that's both clinically effective AND genuinely easy to drink.   If you're looking for an option to support SIBO or your gut, mBIOTA Elemental may be one to consider. Learn more at mbiota.com and save 20% on their two-week protocol with code GUTIVATE  

In this episode of the UEG Podcast, host Pradeep Mundre is joined by David Sanders, Professor of Gastroenterology at Sheffield and one of the world's leading experts in coeliac disease. Timed with the recent update of the British Society of Gastroenterology coeliac guidelines, the discussion explores why coeliac disease remains frequently underdiagnosed, even in specialist care. Together, they unpack the latest evidence on serology-based diagnosis, optimal biopsy strategies, potential and seronegative coeliac disease, and when HLA testing is truly useful. The episode also covers long-term follow-up, the role of repeat biopsies, ultra-short coeliac disease, and emerging non-dietary therapies — including the realistic prospects of a future “pizza pill”. Check out the newest guidelines on coeliac disease here:https://doi.org/10.1002/ueg2.70119

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Ross Maltz, pediatric gastroenterologist at Nationwide Children's Hospital and Associate Professor at The Ohio State University College of Medicine.  He is Director of the Very Early Onset Inflammatory Bowel Disease (VEOIBD) Program and Research Director of the Inflammatory Bowel Disease Center at Nationwide Children's.He provides a massive update on all things IBD medications, including discussing the latest on biosimilar medications, the medications we have available and their positioning, and new things in the pipeline.Dr. Maltz does not have any conflicts of interest to disclose.Learning objectivesUnderstand the safety and efficacy of biosimilar medications for children with IBD.Review the latest guidance on medications available for treatment of children with IBD.Discuss opportunities for advocacy to provide better access to IBD medications for children.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Case studies reveal how non-celiac gluten sensitivity can drive psychiatric and neurological symptoms, and how diet changes lead to recovery. #GlutenFree #MentalHealth #Autoimmunity #HealthTalks

Send us a textA mouse who can't eat cheese and an owl who loves her anyway—sometimes the simplest stories hold the biggest truths. We welcome author MB Mooney to share how The Mouse Who Couldn't Eat Cheese grew from the life and legacy of Alex, a bright, owl‑loving kid who lived with Crohn's disease and inspired a foundation, Beautiful Beyond the Pain. Instead of a medical explainer, MB wrote a friendship-first tale that helps children understand invisible illness, practice empathy, and see vulnerability as a path to connection.We open up the creative process behind writing for kids and parents at once: crafting a title that hooks curiosity, choosing scenes that feel honest, and striking a tone that respects young readers without sanding down the hard parts. MB explains why children's books are tougher than they look, how early readers—many without any IBD connection—found universal meaning in the story, and what it takes to put your heart on the page when criticism is part of the job. For aspiring authors in the chronic illness community, he shares a practical roadmap: draft freely, revise with audience in mind, find a writing group for accountability and critique, and build resilience for the inevitable one‑star review.We also look ahead to future volumes featuring Alex the Owl, including a potential ADHD story drawn from MB's family experience. Along the way we talk about making invisible illness visible, helping kids self‑advocate, and why every community benefits when friends learn to meet each other's needs with flexibility and care. If you're a parent, patient, educator, or creator looking for stories that heal and tools that help, this conversation is a warm, grounded guide.If the episode resonates, follow the show, share it with a friend, and leave a quick review—your support helps more listeners find thoughtful conversations like this one.Links: MB Mooney's websiteThe Mouse Who Couldn't Eat CheeseCamp Oasis- Crohn's & Colitis Foundation USA A longer interview with MB about his book- Adventures in the Heart of Children's Book Authors podcastLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

As we turn the page on a new year, the neuroendocrine cancer community isn't just reflecting on progress—we're looking ahead. This episode of NETWise explores where the field is going next, and what that future means for patients, caregivers, and clinicians alike.Recorded in connection with the 2025 NETRF Neuroendocrine Cancer Research Symposium, this conversation brings together researchers, physicians, patient advocates, and NETRF leaders to examine the momentum shaping the years ahead.In this episode, you'll hear about:How emerging therapies—from PRRT advances to immune-based and cell therapies—are changing careWhy precision medicine, surface targeting, and biomarkers are defining the next era of researchNETRF's research roadmap, focused on early detection, improved treatments, and precision medicine.The growing role of patient education, self-advocacy, and “thrivership” in living well with NETs and Neuroendocrine CarcinomaHow collaboration across institutions and disciplines is accelerating progress toward better outcomesThis isn't just a vision of the future—it's the work already underway, and the direction the field is moving next.Whether you're a patient, caregiver, clinician, or advocate, this episode offers clear, accessible insights into the breakthroughs that’s driving the research forward.Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF's mission to expand research, awareness, and hope across the NET community. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Po-Hien Ear, PhDAssistant Professor of Surgery (Surgical Oncology & Endocrine Surgery), University of Iowa Carver College of Medicine Martyn Caplin, MD, PhD, FRCPProfessor of Gastroenterology & Tumour Neuroendocrinology, Royal Free Hospital & University College London (UCL) Carl Gay, MD, PhDAssistant Professor, Department of Thoracic/Head & Neck Medical OncologyDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Pamela L. Kunz, MDDirector, Center for Gastrointestinal Cancers, Smilow Cancer Hospital & Yale Cancer CenterChief, GI Medical Oncology, Yale School of Medicine Neil Renwick, MD, PhD, FRCPCAssistant Professor, Department of Pathology & Molecular Medicine, Queen's University(SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhDProfessor of Surgical Pathology, University of California, San Francisco (UCSF) Iacovos Michael, PhDSunnybrook Research institute and University of Toronto Elsa Hadj Bachir, PhDResearch Fellow in Medicine Dana-Farber Cancer Institute Thank you to NETRF staff members Elyse Gellerman and Anna Greene, PhD, and NETRF Board Members Josh Mailman, and Todd Gillman for their contributions to this episode.A special thank you to Jake Dawson and Nancy Lewis for sharing their neuroendocrine cancer journeys. Download a transcript of this episode. The post Episode 51: A New Year— Where We're Going appeared first on NETRF.

Dr. Clarke leads the Association for the Treatment of Neuroplastic Symptoms, a nonprofit aiming to empower people with evidence-based tools to take ownership of their health. His focus is on uncovering how stress and even past experiences can drive physical symptoms like IBS, migraines, fibromyalgia, and more. With board certifications in both Internal Medicine and Gastroenterology, he approaches gut health and pain management through a biopsychosocial lens, encouraging recovery without relying on medications or costly interventions. Coach Eric sits down and deep dives into the science of neurology and how the brain works and how we get neuroplastic conditions and how to treat them   About David Clarke   Only buy what you need, use Think Fitness Life's trusted affiliates when the service/supplement is right for you.  For Physical Assistance Think Fitness Life Coaching is backed by 25 years of Experience guiding people to fitness freedom. Learn more Mention "Kickstart discount" for 10% off your first month.   For Therapy Services we partnered with BetterHelp: A telehealth therapy service connecting people with licensed mental health therapists. Learn more By using the referral link you receive 10% off your first month. Disclaimer: We're here to share ideas and inspiration, not medical advice. Please check with your doctor before making any changes to your health or fitness routine.  

Byrne discusses Dova's recent Late Breaker at the United European Gastroenterology (UEG) Week 2025, where AI re-analysis uncovered treatment effects missed by human readers. He explains how AI may soon become integral to clinical trial design, regulatory review, and drug approval, while predicting how AI-human partnerships will define the future of gastroenterology. Timestamps:01:05 – AI in the TITRATE trial03:18 – Validating clinical endpoints04:16 – AI and human readers16:53 – The next frontier in gastrointestinal AI

Send us a textWhat if the decision you feared most was the one that finally set you free? We sit with Gaylyn Henderson—writer, model, and founder of Gutless and Glamorous—to trace her path from a swift, severe Crohn's diagnosis at fourteen to an ostomy that gave her health, energy, and a voice loud enough to change minds.Gaylynn opens up about the early years when prednisone and 6MP were the only options and hospital stays collided with high school milestones. She explains how stigma around surgery—echoed by culture and sometimes even clinicians—kept her in pain despite worsening Crohn's with fistulas. The turning point came with a loop ileostomy and near-instant relief: weight returned, pain lifted, and daily life felt possible again. That contrast fuels her mission to push back on misinformation, normalize ostomies, and help others avoid years of needless suffering.We explore how a personal blog became a movement. Gaylyn shares the moment she hit “send,” the flood of messages from people who finally felt seen, and how modeling with Aerie made ostomy visibility mainstream. Her nonprofit, Gutless and Glamorous, builds community through modern, welcoming spaces that don't feel like traditional support groups, connecting patients who can check in when symptoms surge and silence sets in.Mental health takes center stage as Gaylyn unpacks the myth of “I should be able to handle this,” and we discuss why therapy and tools like EMDR can help after the crisis has passed. Chronic illness can be isolating; community is part of care. Expect candid talk about advocacy, ostomy life, body image, and the courage to redefine normal on your own terms.If this conversation resonates, tap follow, share it with someone who needs it, and leave a review—your voice helps more people find the support they deserve.Links: Gutless and Glamorous websiteGaylyn on InstagramMore of Gaylyn's story in Elle magazineGaylyn in The MightyLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In this episode of Bowel Sounds, hosts Dr. Jordan Whatley and Dr. Jenn Lee talk to Dr. Naylor Brownell, Pediatric Gastroenterologist and Co-Director of the Pancreatic Disorders Program at the Children's Hospital of Philadelphia, who provides care in the Jill and Mark Fishman Center for Lymphatic Disorders. We talk about lymphatic conditions and their effect on the GI tract, as well as the diagnosis and management of primary intestinal lymphangiectasia.Learning Objectives1.  Understand the structure and function of the lymphatic system2.  Describe the causes of protein losing enteropathy (PLE) and how they are diagnosed3.  Understand the management of children with primary intestinal lymphangiectasiaLinkshttps://www.chop.edu/centers-programs/jill-and-mark-fishman-center-lymphatic-disordersSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

In this video we cover Gastric Cancer / Stomach Cancer, looking at risk factors for it as well as what are the signs and symptoms of Gastric Cancer (with Troisier's sign!). Also includes the most common locations of gastric cancer, how gastric cancer is diagnosed (including staging), and how is gastric cancer treated. PDFs available at: https://rhesusmedicine.com/pages/gastroenterologyFor more medicine videos consider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineVideo Timestamps:0:00 How common is Gastric Cancer0:10 Risk Factors for Gastric Cancer1:07 Where is Gastric Cancer most common? 1:19 Types of Gastric Cancer1:35 Most Common Site of Gastric Cancer (Which part of the stomach is most commonly affected)1:49 Signs and Symptoms of Gastric Cancer (Gastric Cancer Symptoms) 2:39 What is Troisier's Sign? (Virchows Node)2:51 Gastric Cancer Diagnosis3:10 Gastric Cancer Staging4:03 Gastric Cancer Prognosis4:35 Gastric Cancer TreatmentLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesWorld Journal of Gastroenterology, 2008. Role of symptoms in diagnosis and outcome of gastric cancer. World Journal of Gastroenterology, 14(8), pp.1149–1155. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690660/. PMCMachlowska, J., Baj, J., Sitarz, M., Maciejewski, R. & Sitarz, R., 2020. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21(11):4012. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312039/. PubMedWikipedia, 2025. Stomach carcinoma / Gastric cancer. [online] Available at: https://en.wikipedia.org/wiki/Stomach_carcinoma.ScienceDirect Topics, 2025. Stomach carcinoma – Medicine and Dentistry. [online] Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/stomach-carcinoma. ScienceDirectWorld Health Organization (WHO), 2025. Cancer fact sheet. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/cancer.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

A look at Colorectal Cancer, the 3rd most common cancer worldwide. We go into the risk factors of colorectal cancer, the signs and symptoms of colorectal cancer (and how they change based on location of the cancer), the diagnosis and screening, as well as treatment of colorectal cancer and its prognosis. PDFs available here: https://rhesusmedicine.com/pages/general-surgeryConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 Intro - Colorectal Cancer Epidemiology 0:12 Colorectal Cancer Risk Factors1:41 Colorectal Cancer Pathology (Polyps & Paris Classification)2:36 Signs and Symptoms of Colorectal Cancer4:20 How is Colorectal Cancer diagnosed? 5:53 Treatment of Colorectal Cancer7:15 What is the prognosis of Colorectal CancerLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesBowel Cancer UK, 2025. About bowel cancer. [online] Available at: https://www.bowelcanceruk.org.uk/about-bowel-cancer/bowel-cancer/. Bowel Cancer UKEndoscopy Campus, 2025. Paris classification – Early cancer. [online] Available at: https://www.endoscopy-campus.com/en/classifications/paris-classification-early-cancer/. endoscopy-campus.comRubio, C.A., Thomeer, M., Nordenskjöld, O., Gaudio, E. & Wallin, J.A., 2007. Malignant colorectal polyps: A review. World Journal of Gastroenterology, 13(30), pp.4141–4146. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896747/. PMCAmerican Cancer Society, 2025. Colon & rectal cancer risk factors. [online] Available at: https://www.cancer.org/cancer/colon-rectal-cancer/causes-risks-prevention/risk-factors.html.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

On this episode Fred Goldstein invites Sheena Crosby, PharmD, BCGP, Inflammatory Bowel Disease Clinical Pharmacist at the Mayo Clinic in Florida. Sheena breaks down the American College of Gastroenterology's (ACG) updated guidelines for ulcerative colitis and Crohn's disease, highlighting major shifts in treatment strategy, including the move toward earlier use of advanced therapies and updated goals focused on symptom control, mucosal healing, and sustained remission. She also outlines the critical payer considerations emphasized in the guidelines—from eliminating unnecessary step-therapy requirements to ensuring timely access to induction and maintenance therapy—changes that have direct implications for patient outcomes and health-system performance. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Send us a textMicroplastics are everywhere—but what are they doing inside the human body?In this episode of Causes or Cures, Dr. Eeks speaks with Dr. Christian Pacher-Deutsch about his lastest study and the growing evidence that micro- and nanoplastics may affect the digestive system, the gut microbiome, and long-term health. He explains why this problem has reached crisis level. Rather than focusing on dramatic claims or quick fixes, this conversation explores what the science actually shows, including how probiotics may help mitigate some of the harmful effects of microplastics...not by breaking them down, but by supporting gut integrity and immune balance.We discuss:What microplastics and nanoplastics are, how they're formed, and where human exposure comes fromWhy nanoplastics may be especially concerning due to their size and biological interactionsThe range of health effects microplastics have been linked to, including immune, neurological, reproductive, and carcinogenic effectsHow microplastics may disrupt the gastrointestinal tract, including digestion, inflammation, barrier function, and gut permeabilityWhat the microbiome is and why it plays a central role in healthWhy probiotics were considered as a potential solution, and what the research foundWhy probiotic bacteria are unlikely to directly degrade plasticsHow probiotics may still help reduce inflammation and support the gut's protective barriersWhether certain bacteria appear more protective than othersThe role of industry collaboration and whether probiotic formulations are being exploredWhether probiotics can realistically help us get ahead of the microplastic crisis, or if they are only part of a larger solutionPractical ways people can reduce exposure, and where reduction may be unrealisticHow diet, including probiotic- and prebiotic-rich foods, might help mitigate riskWhat this research changed about Dr. Pacher-Deutsch's own habitsWhat's next in microplastics and health researchThis episode offers a clear, evidence-based look at microplastics inside the human body—without panic, hype, or false promises.GUEST BIO: Dr. Pacher-Deutsch is a scientist and researcher in the Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria; Center for Biomarker Research in Medicine (CBmed), Graz, Austria. Work with me? Perhaps we are a good match. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her WEEKLY newsletter here!Support the show

What is a call? How does a person know if God is calling them to mission service? Join in a discussion as these and other questions are addressed.

Send us a textWhat does great IBD care look like when the system won't make it easy? We sit down with Dr. Adam Ehrlich, Section Chief of Gastroenterology at Temple Health and GI fellowship program director, to explore how he builds patient-centered care in an underserved setting—where insurance denials, missing records, and real-life logistics collide with complex disease.We talk about health literacy, trust, and the conversations that actually change outcomes. Adam explains how he frames risks and benefits with clarity, why the “risks of doing nothing” deserve equal airtime, and how he balances mode of therapy—IV, subcutaneous, or oral—against lifestyle, trauma history, pregnancy plans, and coverage rules. We dig into prison medicine's constraints, from medication access to policy barriers around scheduling, and the creative problem-solving required to keep patients safe and informed. He shares why being honest about uncertainty builds credibility, and how an early investment in patient education pays off with better monitoring and shared targets for remission.The episode also gets practical about personalization. We discuss drug levels with infliximab when severe colitis “loses” medication into the stool, when it's wise to de-escalate dosing, and how habits from flare days can persist after inflammation settles. Adam offers tools to retrain routines, navigate IBS overlap, and align care with quality of life goals like driving, work travel, and showing up at a kid's soccer game without anxiety. As a fellowship director, he reveals how he equips new gastroenterologists to handle today's broader therapy menu, think beyond flowcharts, and advocate through insurance barriers with persistence and purpose.If this conversation resonates, tap follow, share it with someone who needs it, and leave a quick review. Your support helps more people find practical, human-centered IBD care.Links and organizations to follow! Color of Gastrointestinal Illness (COGI)- mission to improve quality of life for BIPOC who are affected by IBD and other GI issues. The Stephanie A. Wynn Foundation - mission to eliminate health disparities and improve outcomes for individuals and communities affected by Inflammatory Bowel Diseases through comprehensive support services, with priority given to underserved populations facing the greatest barriers to healthcare.Strategic Alliance for Intercultural Advocacy in GI (SAIA)- mission to create culturally sensitive resources, research, and education for patients, caregivers and healthcare providers managing chronic GI conditions in order to minimize delays, dispel stigma, promote early diagnosis, and improve access to treatment for all.Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Pediatrician Dr. Jill Schaffeld consults Dr. Scott Pentiuk and Dr. Alex Nasr from the Division of Gastroenterology, Hepatology, and Nutrition on ingested foreign bodies. Episode recorded on July 31, 2025.  Resources discussed in this episode: Ingested Foreign Bodies - Community Practice Support Tool Financial Disclosure:  The following relevant financial relationships have been disclosed: None All relevant financial relationships listed have been mitigated. Remaining persons in control of content have no relevant financial relationships. To Claim Credit: Click "Launch Activity." Click "Launch Website" to access and listen to the podcast. After listening to the entire podcast, click "Post Test" and complete.   Accreditation In support of improving patient care, Cincinnati Children's Hospital Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Specific accreditation information will be provided for each activity. Physician:  Cincinnati Children's designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Nursing:  This activity is approved for a maximum 0.50 continuing nursing education (CNE) contact hours. ABP MOCpt2: Completion of this CME activity, which includes learner assessment and feedback, enables the learner to earn up to 0.50 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. Cincinnati Children's submits MOC/CC credit for board diplomates.   Credits AMA PRA Category 1 Credits™ (0.50 hours), ABP MOC Part 2 (0.50 hours), CME - Non-Physician (Attendance) (0.50 hours), Nursing CE (0.50 hours)

Low resource settings require much innovation and streamlining resources to meet set goals. With healthcare becoming more commercial and profit driven, missional healthcare in low resource settings faces many challenges. Sustainability is a big question with people finance , and equipment scarce and hard to come by. Missional models of healthcare often run into hurdles of sustainability, longevity and relevance even as healthcare slowly turns into business. In this setting of multifactorial challenges and increasing compliances how can missional healthcare be relevant and sustainable? Many saints of God have committed their lives to fulfil this great commission in some of the most underserved and unreached areas of the world. With the birth of Emmanuel Hospital Association (EHA) a different model of missional healthcare emerged in India. Over the last 55 years of its existence, EHA has shown that through all the challenges, this may be one of the ways to sustain missional healthcare in areas of need. With increasing divide between the rich and poor, overwhelmed government systems, a ruthless insurance system, and high end corporate healthcare, it is still possible for missional healthcare to provide low cost, high quality, technologically advanced care to people in need while remaining sustainable. We bring lessons from India and our experience with Emmanuel Hospital Association over the last 3 decades.

Fecal incontinence (FI) affects nearly 8% of adults worldwide, yet many people suffer in silence due to embarrassment, confusion, or the belief that nothing can be done. This episode is here to change that. We're joined by Dr. John William Blackett, gastroenterologist and lead author of "Fecal Incontinence in Adults: New Therapies," published in The American Journal of Gastroenterology. Dr. Blackett offers a compassionate, patient-centered overview of FI, including common causes, diagnostic testing, and the full range of treatment options available today—highlighting newer and emerging therapies. If you've experienced unexpected leakage, urgency, staining, or difficulty controlling bowel movements—or if you support someone who has—this conversation provides clarity, reassurance, and practical guidance. Effective treatments exist, and help is available. This episode is produced in collaboration with the American College of Gastroenterology Patient Care Committee.

In this episode of Bowel Sounds, hosts Dr. Amber Hildreth and Dr. Peter Lu talk to Dr. Tom Wallach, Assistant Professor of Pediatrics at SUNY Downstate, Chief of Pediatric Gastroenterology, Pediatric GI Fellowship director, and Research Director of Pediatrics. We talk about experience based research and how to implement these tools into medical education.Learning objectivesDefine experience based researchUnderstand how to incorporate experience based research into medical educationExplore the variety of tools available to scientists at all levels of training to conduct researchSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

In this episode, Michael S. Smith, MD, MBA, Associate System Chief of Gastroenterology for Clinical Operations and Strategic Planning at The Mount Sinai Health System and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses key trends in GI care, late cancellations, telehealth, AI adoption, and how strong leadership and culture can support both providers and patients.

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.Topics covered include:Available agents for second-line treatment of PBC An overview of clinical trial data supporting second-line agents:Obeticholic acid (OCA)BezafibrateElafibranorSeladelparThis episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3rPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.Topics covered include:Mechanisms of pruritus and fatigue in PBCNonpharmacologic treatment optionsAn overview of clinical trial data supporting second-line agents for symptom management:BezafibrateElafibranorSeladelparInvestigational agents:VolixibatLinerixibatSetanaxibThis episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:How and when to assess treatment responseRisk factors in PBCBiochemical treatment response and fibrosis stage as predictors of transplant-free survivalDynamics of liver stiffness measurements and clinical outcomes in PBC The importance of bilirubin and alkaline phosphatase normalizationThis episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008

This week on Health Matters, Courtney sits down with Dr. Braden Kuo, Chief of the Division of Digestive & Liver Diseases at NewYork-Presbyterian and Columbia. Dr. Kuo covers common gut problems during the holiday season, a time of indulgent meals and treats. From bloat to heartburn to travel-related stomach issues, Dr. Kuo is a trove of information and practical tips for navigating holiday festivities with good choices for your gut.  ___ Dr. Braden Kuo is a leading neurogastroenterologist specializing in gastrointestinal motility and the relationship between the brain, nervous system and digestive system. He is the Chief of the Division of Digestive and Liver Diseases at NewYork-Presbyterian/ColumbiaUniversity Irving Medical Center and Columbia University Vagelos College of Physicians andSurgeons. Dr. Kuo received his medical degree from Jefferson Medical College and completed his residency at the University of Texas Southwestern Medical Center before arriving at Massachusetts General Hospital, where he served as director of the Center for Neurointestinal Health. He also completed formal training in clinical research, earning a Master of Science from the Harvard T.H. Chan School of Public Health, and subspecialty training in neurogastroenterology and motility at Mayo Clinic.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Send us a textThe hardest part isn't always the pain; it's the fog—those days when the labels keep changing, the meds blur together, and the bills are louder than your body. That's where Stephanie A. Wynn stepped in, transforming her Crohn's journey into a movement for clarity, access, and equity.We sit down with Stephanie—author, podcaster, and founder of the Stephanie A. Wynn Foundation—to unpack how a misdiagnosis spiral, two heartbreaking pregnancy losses, and a sixth GI finally led to answers and action. She walks us through the IBD Patient Navigator Program she built to connect people with the care team they actually need: GI, primary care, mental health, dietitian, pelvic floor therapist, and, when needed, a colorectal surgeon. We talk about practical tools that change outcomes—recording appointments, coming with three priority questions, tracking symptoms and meals, and learning your labs so they can become signals instead of mysteries.Stephanie also opens up her book Navigating IBD: A Six-Week Blueprint for Better Gut Health which she designed to slow overwhelm and teach the language of care including treatment decisions, and what “knowing your numbers” truly means. We dig into clinical trials—why she calls it clinical research, how to qualify, what to ask about aftercare, and ways to participate through labs or tissue samples to boost representation. We tackle health disparities and social determinants of health head-on: transportation, refrigeration for meds, school support, and why trust is built by showing up with real solutions.This is a conversation about agency and community for anyone living with Crohn's disease or ulcerative colitis. You'll leave with a sharper checklist, a stronger voice, and a reminder that you are not alone—and that the right tools and team can change everything.If this helped you, follow the show, leave a quick review, and share it with someone who needs a clear path forward today.Links: Link to Stephanie's IBD bookThe Stephanie A. Wynn FoundationRacial and Ethnic Disparities in Medical Advancements and Technologies- Kaiser Family Foundation Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

https://BetterHealthGuy.comWhy You Should Listen:  In this episode, you will learn about the many pieces that contribute to the puzzle of Long COVID. About My Guest: My guest for this episode is Dr. Robin Rose.  Robin Rose, DO, author of "The 28-Day Gut Fix," is a double board-certified specialist in Gastroenterology and Internal Medicine, specializing in gut health and Long COVID.  She is founder and CEO of Terrain Health where she practices next-generation precision healthcare, integrating systems biology with an innovative approach that requires a deep understanding of each person's biochemical, genetic, and lifestyle factors.  Her comprehensive approach prioritizes patient-centered care by creating healthcare interventions that are more precise, personalized, predictive, participatory and preventative.  Her philosophy is deeply rooted in healing her patients from the inside out so they will age LESS.  Dr. Robin received her bachelor's degree in Behavioral Neuroscience from Lehigh University, graduating with honors. She then went on to obtain her master's degree in Neuropsychology from New York University. Dr. Robin received her medical degree from the New York College of Osteopathic Medicine, graduating with honors, and was inducted into the Psi Sigma Alpha Osteopathic National Honor Society. She did her postgraduate training in Internal Medicine, followed by fellowship in Gastroenterology and Hepatology, at Beth Israel Medical Center in New York City, and holds board certifications in both disciplines.  Dr. Robin practices longevity medicine teaching women and men how to achieve their best selves by restoring and optimizing gut health, balancing hormones, and proactively managing metabolic, cardiovascular, and brain health.  Maximizing these outcomes will pave the way for optimal healthspan and performance and looking and feeling your best! Key Takeaways: What is Long COVID? What are the symptoms or phenotypes of Long COVID? How does SARS-CoV-2 act as a bacteriophage impacting our microbiome? Who is more likely to develop Long COVID? Should ongoing exposures be avoided even if someone already had COVID? What are ACE2 receptors?  Furin cleavage site?  Receptor binding domain? What testing is used to explore Long COVID? Is there a direct test available for spike protein? What role does coagulation and vascular health play in Long COVID? How do MCAS, POTS, and EDS enter the Long COVID discussion? What is the role of neuroinflammation in Long COVID? Has cognitive decline accelerated during the pandemic era? What role do mitochondria play in Long COVID? What iron dysregulation pattern is commonly observed? Have more cancers been seen since the start of the pandemic? Do EMFs play a role in those struggling with Long COVID? How is treatment of the sensitive patient approached? What is the high-level treatment methodology for those struggling with Long COVID? How are bacteriophages addressed and the microbiome restored? What is a spike protein binder? What is the role of senolytics in removing spike proteins from the body? Where does autoimmunity enter the COVID conversation? What is Vedicinals®9? Is there a place for Ivermectin? How should the sinuses be supported? Do EBOO or TPE play a role in Long COVID recovery? Connect With My Guest:  TerrainHealth.org Related Resources: Vedicinals® USA Vedicinals®9 Sequesterol® Senolescence® Neuralescence® Night Use code BETTERHEALTH for 25% off Our Wellness Journey Spike Protein Testing - https://ourwellnessjourney.us Interview Date: November 17, 2025 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode225. Support the Show: To support the show and Buy Me a Coffee, visit https://betterhealthguy.link/BuyMeACoffee. Additional Information: To learn more, visit https://BetterHealthGuy.com. Follow Me on Social Media: Facebook - https://facebook.com/betterhealthguy Instagram - https://instagram.com/betterhealthguy X - https://twitter.com/betterhealthguy TikTok - https://tiktok.com/@betterhealthguy Disclosure: BetterHealthGuy.com is an affiliate of Vedicinals USA. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

Did you know that a single crumb of bread is enough to cause an autoimmune response in children with celiac disease? Dr. Pankaj Vohra, Professor of Pediatrics and Board-Certified Pediatric Gastroenterologist, joins medical student Andrea Smith to discuss the evaluation and management of celiac disease, as well as essential guidance for following a gluten-free diet. Specifically, they will: Review the epidemiology of celiac disease and identify common symptoms and presentations of celiac disease Describe the pathophysiology of celiac disease including histopathological changes to the duodenum Identify diagnostic tests and criteria for diagnosing celiac disease in the pediatric population Identify common sources of gluten and the basics of identifying gluten on food labels Discuss typical management of celiac disease including appropriate screening tests and managing accidental gluten ingestion Special thanks to Dr. Rebecca Yang and Dr. Neeharika Bade for peer reviewing this episode. CME available free with sign up: Link coming soon! References: Bolia, R., & Thapar, N. (2023). Celiac Disease in Children: A 2023 Update. In Indian Journal of Pediatrics. Springer. https://doi.org/10.1007/s12098-023-04659-w Gidrewicz, D., Potter, K., Trevenen, C. L., Lyon, M., & Butzner, J. D. (2015). Evaluation of the ESPGHAN celiac guidelines in a North American pediatric population. American Journal of Gastroenterology, 110(5), 760–767. https://doi.org/10.1038/ajg.2015.87 Hill, I. D., Fasano, A., Guandalini, S., Hoffenberg, E., Levy, J., Reilly, N., & Verma, R. (2016). NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 156–165. https://doi.org/10.1097/MPG.0000000000001216 Husby, S., Koletzko, S., Korponay-Szabó, I., Kurppa, K., Mearin, M. L., Ribes-Koninckx, C., Shamir, R., Troncone, R., Auricchio, R., Castillejo, G., Christensen, R., Dolinsek, J., Gillett, P., Hróbjartsson, A., Koltai, T., Maki, M., Nielsen, S. M., Popp, A., Størdal, K., … Wessels, M. (2020). European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. In Journal of Pediatric Gastroenterology and Nutrition (Vol. 70, Issue 1, pp. 141–156). Lippincott Williams and Wilkins. https://doi.org/10.1097/MPG.0000000000002497 Nenna, R., Tiberti, C., Petrarca, L., Lucantoni, F., Mennini, M., Luparia, R. P. L., Panimolle, F., Mastrogiorgio, G., Pietropaoli, N., Magliocca, F. M., & Bonamico, M. (2013). The celiac iceberg: Characterization of the disease in primary schoolchildren. Journal of Pediatric Gastroenterology and Nutrition, 56(4), 416–421. https://doi.org/10.1097/MPG.0b013e31827b7f64 Sahin, Y. (2021). Celiac disease in children: A review of the literature. In World Journal of Clinical Pediatrics (Vol. 10, Issue 4, pp. 53–71). Baishideng Publishing Group Co. https://doi.org/10.5409/wjcp.v10.i4.53 Salden, B. N., Monserrat, V., Troost, F. J., Bruins, M. J., Edens, L., Bartholomé, R., Haenen, G. R., Winkens, B., Koning, F., & Masclee, A. A. (2015). Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Alimentary Pharmacology and Therapeutics, 42(3), 273–285. https://doi.org/10.1111/apt.13266 Schuppan, D., Mäki, M., Lundin, K. E. A., Isola, J., Friesing-Sosnik, T., Taavela, J., Popp, A., Koskenpato, J., Langhorst, J., Hovde, Ø., Lähdeaho, M.-L., Fusco, S., Schumann, M., Török, H. P., Kupcinskas, J., Zopf, Y., Lohse, A. W., Scheinin, M., Kull, K., … Greinwald, R. (2021). A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 385(1), 35–45. https://doi.org/10.1056/nejmoa2032441 Tack, G. J., van de Water, J. M. W., Bruins, M. J., Kooy-Winkelaar, E. M. C., van Bergen, J., Bonnet, P., Vreugdenhil, A. C. E., Korponay-Szabo, I., Edens, L., von Blomberg, B. M. E., Schreurs, M. W. J., Mulder, C. J., & Koning, F. (2013). Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World Journal of Gastroenterology, 19(35), 5837–5847. https://doi.org/10.3748/wjg.v19.i35.5837 Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136–160

Welcome to the Choosing Wisely Campaign series! This is the fifth and final episode of our 5-part series exploring the ABIM Foundation's Choosing Wisely Lists. This campaign aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. Our last case-based episode focuses on a school-aged male presenting with new-onset enuresis. After a discussion of the differential diagnosis and evidence-based evaluation strategies, we apply recommendations from multiple AAP Choosing Wisely lists to create a care plan that is safe, resource-conscious, and child-centered. Throughout this episode, we'll highlight how ethical care principles—beneficence, nonmaleficence, autonomy, and justice—guide high-value decision-making and help us avoid unnecessary imaging, laboratory studies, and interventions that add cost without improving outcomes. This familiar case in pediatrics is worthy of a rewind to relisten to a throwback episode that will reinforce your skills and emphasize the clinical diagnosis and management without added diagnostics, referrals, or medications.  This case closes out our series on Choosing Wisely in Pediatrics, but the principles we've explored should continue to inform your practice every day. If you missed earlier episodes, rewind to learn more about the campaign's background and listen to cases on fever and cough, gastroenterology presentations, and more.   Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Modified rMETRIQ Score: 15/15 What does this mean?   Competencies: AACN Essentials: 1: 1.1 g; 1.2 f; 1.3 d, e 2: 2.1 d, e; 2.2 g; 2.4 f, g; 2.5 h, i, j, k 7: 7.2 g, h, k 9: 9.1i, j; 9.2 i, j; 9.3 i, k NONPF NP Core Competencies: 1: NP 1.1h; NP 1.2 k, m; NP 1.3 f, j, h 2: NP 2.1 j, g; NP 2.2 k, n; NP 2.4 h, i; NP 2.5 k, l, m, n, o 7: NP 7.2 m 9: NP 9.1 m, n; NP 9.2 n; NP 9.3 p References: AAP Section on Emergency Medicine & Canadian Association of Emergency Physicians. (2022). Five things physicians and patients should question. Retrieved from https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWEmergencyMedicine.pdf AAP Section on Gastroenterology, Hepatology, and Nutrition. (2023). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWGastroenterology.pdf AAP Section on Urology. (2022). Five things physicians and patients should question. Retrieved from https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWUrology.pdf Daniel, M., Szymanik-Grzelak, H., Sierdziński, J., Podsiadły, E., Kowalewska-Młot, M., & Pańczyk-Tomaszewska, M. (2023). Epidemiology and Risk Factors of UTIs in Children-A Single-Center Observation. Journal of personalized medicine, 13(1), 138. https://doi.org/10.3390/jpm13010138 McMullen, P.C., Zangaro, G., Selzer, C., Williams, H. (2026). Nurse Practitioner Claims and the National Practitioner Data Bank: Trends, Analysis, and Implications for Nurse Practitioner Education and Practice. Journal for Nurse Practitioners, 22(1), p. 105569, https://doi-org.proxy.lib.duke.edu/10.1016/j.nurpra.2025.105569 Tabbers, M. M., DiLorenzo, C., Berger, M. Y., Faure, C., Langendam, M. W., Nurko, S., Staiano, A., Vandenplas, Y., Benninga, M. A., European Society for Pediatric Gastroenterology, Hepatology, and Nutrition, & North American Society for Pediatric Gastroenterology (2014). Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. Journal of pediatric gastroenterology and nutrition, 58(2), 258–274. https://doi.org/10.1097/MPG.0000000000000266 UCSF Benioff Children's Hospitals. (n.d.). Constipation & urologic problems. https://www.ucsfbenioffchildrens.org/conditions/constipation-and-urologic-problems Vaughan, D. (2015). The Challenger Launch Decision: Risky Technology, Deviance, and Culture at NASA. University of Chicago Press. DOI: 10.7208/chicago/9780226346960.001.0001 Wilbanks, Bryan A. PhD, DNP, CRNA. Evaluation of Methods to Measure Production Pressure: A Literature Review. Journal of Nursing Care Quality 35(2):p E14-E19, April/June 2020. | DOI: 10.1097/NCQ.0000000000000411